Medicine and Dentistry
Pancreas Cancer
77%
Neoplasm
59%
Pancreas Adenocarcinoma
58%
Nodular Melanoma
44%
Overall Survival
41%
Malignant Neoplasm
38%
Disease
35%
Surgery
31%
Cholangiocarcinoma
26%
Metastatic Carcinoma
23%
Adenocarcinoma
22%
Adjuvant Therapy
19%
Progression Free Survival
17%
Pembrolizumab
15%
Clinical Trial
14%
Metastatic Melanoma
14%
DNA Mismatch Repair
13%
Brain Metastasis
12%
Neoadjuvant Therapy
12%
Personalized Medicine
11%
Odds Ratio
11%
Immune Checkpoint Inhibitor
11%
Family History
11%
Biological Marker
10%
Recurrent Disease
10%
Fibroblast Growth Factor Receptor 2
9%
Targeted Therapy
9%
Adjuvant Chemotherapy
9%
Metastatic Colorectal Cancer
8%
Gemcitabine
8%
Adverse Event
8%
Oncology
8%
Chemoradiotherapy
8%
Body Mass Index
7%
Prognostic Factor
7%
Pooled Analysis
7%
Melanoma
7%
Colorectal Cancer
7%
Phase II Trials
7%
Hazard Ratio
7%
Arm
6%
Cancer Therapy
6%
Ipilimumab
6%
Gallbladder Cancer
6%
Tumor Gene
6%
Pancreas Carcinoma
5%
Genome Wide Association Study
5%
Bevacizumab
5%
Fibroblast Growth Factor Receptor
5%
Prevalence
5%
Keyphrases
Pancreatic Cancer
100%
Confidence Interval
47%
Melanoma
35%
Overall Survival
26%
Pancreatic Ductal Adenocarcinoma
25%
Phase II Trial
24%
Pancreatic Adenocarcinoma
24%
Metastatic Melanoma
23%
Pancreatic Cancer Risk
22%
Odds Ratio
20%
Genome-wide Association Study
20%
Cancer Patients
20%
Mayo Clinic
19%
Adjuvant Therapy
17%
Gemcitabine
16%
Bevacizumab
16%
SNP
15%
Brain Metastases
12%
Single nucleotide Polymorphism
12%
Germline mutation
12%
Chemotherapy
11%
Metastatic Colorectal Cancer (mCRC)
11%
Polymorphism
11%
Nab-paclitaxel
11%
Median Overall Survival
11%
Tumor
11%
Metastatic Pancreatic Ductal Adenocarcinoma
11%
In Cancer
11%
Family History
10%
Stage IV Melanoma
10%
Clinical Outcomes
10%
Phase II Study
10%
Cancer Cases
9%
Neoadjuvant Therapy
9%
Hazard Ratio
9%
Immune Checkpoint Inhibitors
9%
Cancer Treatment
9%
Progression-free Survival
9%
Irinotecan
9%
Randomized Phase II Trial
9%
First-degree Relatives
9%
Germ Cells
9%
Peptide Vaccine
8%
Pancreatic Carcinoma
8%
Personalized Medicine
8%
Biliary Tract Carcinoma
8%
Phase I Trial
8%
NCCTG
8%
Metastatic Disease
8%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
48%
Malignant Neoplasm
42%
Pancreas Cancer
42%
Melanoma
39%
Pancreas Adenocarcinoma
32%
Disease
31%
Overall Survival
30%
Metastatic Melanoma
29%
Progression Free Survival
26%
Bile Duct Carcinoma
20%
Chemotherapy
18%
Phase II Trials
18%
Adverse Event
18%
Bevacizumab
17%
Gemcitabine
16%
Pembrolizumab
16%
Metastatic Colorectal Cancer
14%
Paclitaxel
14%
Clinical Trial
14%
Immune Checkpoint Inhibitor
13%
Adenocarcinoma
13%
Irinotecan
12%
Oxaliplatin
10%
Pancreas Carcinoma
8%
Dabrafenib
8%
Trametinib
8%
Carboplatin
8%
Chemoradiation Therapy
8%
Colorectal Cancer
8%
Monotherapy
7%
Biological Marker
7%
Metastasis
7%
Immunotherapy
7%
Antitumor Activity
7%
Phase I Trials
6%
Fibroblast Growth Factor Receptor 2
6%
Fibroblast Growth Factor Receptor
5%
Capecitabine
5%
Maximum Tolerated Dose
5%
Fluorouracil
5%